{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:08:02Z","timestamp":1790633282035,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["140343"],"award-info":[{"award-number":["140343"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.xcrm.2023.100961","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T10:40:52Z","timestamp":1677753652000},"page":"100961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["A bispecific T\u00a0cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4729-8863","authenticated-orcid":false,"given":"Roeland","family":"Lameris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjen M.","family":"Ruben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Iglesias-Guimarais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milon","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe","family":"Veth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur S.","family":"van de Bovenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"de Weerdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjeng","family":"Horbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Winograd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob C.","family":"Roovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton E.P.","family":"Adang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.H.I.","family":"Parren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"van der Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.100961_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100961_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2023.100961_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2023.100961_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl","volume":"385","author":"Nathan","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib5","doi-asserted-by":"crossref","first-page":"e000621","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J.\u00a0Immunother. cancer"},{"key":"10.1016\/j.xcrm.2023.100961_bib6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T\u00a0cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2023.100961_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T\u00a0cell engager treatment in T\u00a0cell-cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12923","article-title":"Immune recognition of phosphoantigen-butyrophilin molecular complexes by \u03b3\u03b4 T\u00a0cells","volume":"298","author":"Uldrich","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2023.100961_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.trecan.2020.11.008","article-title":"Targeting the mevalonate pathway in cancer","volume":"7","author":"Juarez","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2023.100961_bib10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T\u00a0cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2023.100961_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T\u00a0cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2023.100961_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human gammadelta T Cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.100961_bib13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib14","doi-asserted-by":"crossref","first-page":"e1284723","DOI":"10.1080\/2162402X.2017.1284723","article-title":"Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2023.100961_bib15","first-page":"81","article-title":"Efficacy and safety of \u03b3\u03b4T cell-based tumor immunotherapy: a meta-analysis","volume":"28","author":"Buccheri","year":"2014","journal-title":"J.\u00a0Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.xcrm.2023.100961_bib16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","article-title":"Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100961_bib17","doi-asserted-by":"crossref","first-page":"e1375641","DOI":"10.1080\/2162402X.2017.1375641","article-title":"A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V\u03b39V\u03b42-T cells","volume":"7","author":"de Bruin","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2023.100961_bib18","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","article-title":"Selective recruitment of \u03b3\u03b4 T\u00a0cells by a bispecific antibody for the treatment of acute myeloid leukemia","volume":"35","author":"Ganesan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2023.100961_bib19","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1078-0432.CCR-20-4576","article-title":"A bispecific single-domain antibody boosts autologous V\u03b39V\u03b42-T cell responses toward CD1d in chronic lymphocytic leukemia. Clin","volume":"27","author":"de Weerdt","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100961_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/2326-6066.CIR-20-0138","article-title":"A bispecific antibody antagonizes prosurvival CD40 signaling and promotes V\u03b39V\u03b42 T\u00a0cell-mediated antitumor responses in human B-cell malignancies","volume":"9","author":"de Weerdt","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2023.100961_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","article-title":"The regulatory role of invariant NKT cells in tumor immunity","volume":"3","author":"McEwen-Smith","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2023.100961_bib22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T\u00a0cells in cancer immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib23","first-page":"1054","article-title":"A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response. Nat","volume":"1","author":"Lameris","year":"2020","journal-title":"Nat. Can. (Que.)"},{"key":"10.1016\/j.xcrm.2023.100961_bib24","doi-asserted-by":"crossref","first-page":"632687","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.xcrm.2023.100961_bib26","first-page":"809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"15","author":"Rossotti","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.xcrm.2023.100961_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl","volume":"380","author":"Scully","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","article-title":"Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody\u00ae targeting the DR5 receptor. Cancer Chemother","volume":"75","author":"Papadopoulos","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.xcrm.2023.100961_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s10875-013-9915-0","article-title":"Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-\u03b1 receptor 1","volume":"33","author":"Holland","year":"2013","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib30","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.100961_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2141.2003.04429.x","article-title":"Valpha24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy","volume":"122","author":"Takahashi","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2023.100961_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J.\u00a0Immunother. cancer"},{"key":"10.1016\/j.xcrm.2023.100961_bib33","doi-asserted-by":"crossref","first-page":"e48927","DOI":"10.15252\/embr.201948927","article-title":"ER stress in antigen-presenting cells promotes NKT cell activation through endogenous neutral lipids","volume":"21","author":"Govindarajan","year":"2020","journal-title":"EMBO Rep."},{"key":"10.1016\/j.xcrm.2023.100961_bib34","doi-asserted-by":"crossref","first-page":"23671","DOI":"10.1073\/pnas.1910097116","article-title":"Sterile activation of invariant natural killer T\u00a0cells by ER-stressed antigen-presenting cells. Proc. Natl. Acad. Sci. U","volume":"116","author":"Bedard","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2023.100961_bib35","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2014-04-567198","article-title":"Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK","volume":"124","author":"Krysov","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.100961_bib36","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.1073\/pnas.0901228106","article-title":"Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer","volume":"106","author":"Bai","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2023.100961_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T\u00a0cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.100961_bib38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.20051777","article-title":"A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d\/glycolipid recognition","volume":"203","author":"Kjer-Nielsen","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib39","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.4049\/jimmunol.175.8.5471","article-title":"In\u00a0vivo immunomanipulation of V gamma 9V delta 2 T\u00a0cells with a synthetic phosphoantigen in a preclinical nonhuman primate model","volume":"175","author":"Sicard","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib40","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.4049\/jimmunol.170.7.3696","article-title":"Conservation of nonpeptide antigen recognition by rhesus monkey V gamma 2V delta 2 T\u00a0cells","volume":"170","author":"Wang","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/imm.12635","article-title":"Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features","volume":"149","author":"Lameris","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2023.100961_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clim.2016.06.012","article-title":"Highly specific and potently activating V\u03b39V\u03b42-T cell specific nanobodies for diagnostic and therapeutic applications","volume":"169","author":"de Bruin","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clim.2011.10.006","article-title":"Activated iNKT cells promote V\u03b39V\u03b42-T cell anti-tumor effector functions through the production of TNF-\u03b1. Clin","volume":"142","author":"Schneiders","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib44","first-page":"670391","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Front","volume":"12","author":"Wang","year":"2021","journal-title":"Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-017-0074-5","article-title":"Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL","volume":"6","author":"N\u00e4gele","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2023.100961_bib46","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T cell\u2013redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.100961_bib48","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.100961_bib49","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T\u00a0cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2023.100961_bib54","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.immuni.2013.11.001","article-title":"Crystal structure of V\u03b41 T\u00a0cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human \u03b3\u03b4 T\u00a0cells","volume":"39","author":"Luoma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2023.100961_bib55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.xcrm.2023.100961_bib50","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1182\/blood-2011-04-348490","article-title":"Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function","volume":"119","author":"McMillin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.100961_bib51","doi-asserted-by":"crossref","DOI":"10.2310\/7290.2009.00007","article-title":"In\u00a0vivo pharmacodynamic imaging of proteasome inhibition","volume":"8","author":"Kimbrel","year":"2009","journal-title":"Mol. Imag."},{"key":"10.1016\/j.xcrm.2023.100961_bib52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1074\/jbc.M308803200","article-title":"Direct measurement of antigen binding properties of CD1 proteins using fluorescent lipid probes","volume":"279","author":"Im","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.100961_bib53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1084\/jem.186.1.109","article-title":"Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T\u00a0cells","volume":"186","author":"Exley","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib56","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20112655","article-title":"Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization","volume":"209","author":"McCoy","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.100961_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-0345-0_14","article-title":"Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines","volume":"1139","author":"Lameris","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2023.100961_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0022-1759(84)90450-2","article-title":"Serum-free medium for generation and propagation of functional human cytotoxic and helper T\u00a0cell clones","volume":"72","author":"Yssel","year":"1984","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.xcrm.2023.100961_bib59","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/eji.201242531","article-title":"The majority of CD1d-sulfatide-specific T\u00a0cells in human blood use a semiinvariant V\u03b41 TCR","volume":"42","author":"Bai","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2023.100961_bib60","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.100961_bib61","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape. Proc. Natl. Acad. Sci. U","volume":"114","author":"Jain","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:55:41Z","timestamp":1762988141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2666379123000538"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.100961","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bispecific T\u00a0cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.100961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100961"}}